BioPharma Drive: Drug Pricing

JULY 8, 2025

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies.

Targeted Protein Degradation 142

Targeted Protein Degradation Small Molecule Disease Therapies 142

Drug Target Review

JUNE 11, 2025

Carlos specialises in helping pharmaceutical and biotechnology companies develop their in- and out-licensing strategies, with additional expertise and experience in portfolio assessment and prioritisation, drug candidate valuation, valuation and related services.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

The Pharma Data

JUNE 24, 2025

For Revolution Medicines, the funding not only provides critical financial runway but also preserves full strategic autonomy—a rare combination in the biotechnology landscape where promising young companies often trade developmental control for capital through licensing or acquisition.

Drug Development 40

Drug Development Clinical Trials Therapies Drugs 40

Drug Target Review

NOVEMBER 25, 2024

I saw an opportunity which others didn’t, to develop a small molecule targeting a well-known cancer pathway, a master switch of cancer Afterwards, I moved to Germany to work for Merck KGaA, where I headed up the licensing and business development team. I would also advise anyone, young women and men included, to always believe in themselves.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

BMG Labtech

DECEMBER 20, 2024

2 in this blog adapted from this reference under license CC-BY 4.0. Richardson AR, Somerville GA, Sonenshein AL. 2015) Regulating the intersection of metabolism and pathogenesis in Gram-positive bacteria. Microbiology Spectrum 3(3):MBP-0004-2014. doi: 10.1128/microbiolspec.MBP-0004-2014. and Hinshelwood, C. London: Oxford University Press.

Regulations 52

Regulations Laboratories Research Production 52

DrugBank

JUNE 18, 2025

Once a drug completes Phase III trials, companies prepare a New Drug Application or Biologics License Application (BLA) for final review. As clinical development progresses, pharmaceutical companies must submit periodic updates to regulatory agencies, reporting on patient safety data, adverse events, and protocol modifications.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

The Pharma Data

JUNE 26, 2025

Global Licensing and Commercialization Agreement MR-141 is being developed under a global licensing agreement between Viatris and Opus Genetics. Further details on the VEGA-3 trial, including inclusion criteria and study design, are publicly available on ClinicalTrials.gov under the identifier NCT06542497.

Trials 40

Trials Clinical Trials Treatment Licensing 40

Perficient: Drug Development

MARCH 25, 2025

Real technology spend includes observability tools, containers, data platforms, SaaS licensing, AI/ML, and peripheral services, sometimes hand-waved away as shadow IT or just life as part of an unavoidable cost center. Complexity is increasing: multicloud and hybrid environments are the norm.

Engineering 52

Engineering Production Licensing Licensing 52

The Pharma Data

JUNE 15, 2025

Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S. Looking forward, new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is expected to be presented in the second half of 2025, adding depth to the growing body of knowledge surrounding lonvo-z.

Treatment 40

Treatment Therapies Licensing Licensing 40

BioPharma Drive: Drug Pricing

MAY 28, 2025

The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under development by Spero.

Licensing 254

Licensing Licensing FDA 254

The Pharma Data

JUNE 6, 2025

Food and Drug Administration (FDA) granted the therapy Priority Review status in May 2025 following its Biologics License Application (BLA) submission in March, reflecting the agency’s recognition of its potential to address a serious condition with limited treatment options.

Trials 40

Trials Treatment FDA Therapies 40

The Pharma Data

JULY 2, 2025

under license from Zymeworks Inc. , Further approval in these regions also depends on the confirmatory Phase 3 HERIZON-BTC-302 trial. Ziihera is being jointly developed by Jazz Pharmaceuticals and BeOne Medicines Ltd. formerly BeiGene, Ltd.) the original developer. Jazz holds commercialization rights in the U.S.,

Therapies 40

Therapies Trials Medical Schools Pharmaceuticals 40

BioPharma Drive: Drug Pricing

JULY 14, 2025

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. Recommended Reading Investors are waking up to Centessa’s sleepiness drug By Jacob Bell • Sept. Can they keep it?

Drugs 184

Drugs Clinical Trials Therapies Licensing 184

The Pharma Data

JUNE 24, 2025

This financing arrangement gives Revolution Medicines the ability to pursue parallel development programs and scale up global commercialization infrastructure without the need to rely on dilutive equity raises or traditional licensing deals that often require sharing intellectual property rights or profit margins.

Clinical Development 40

Clinical Development Packaging Therapies Treatment 40

Drug Target Review

NOVEMBER 28, 2024

As a result, organisations are left to adopt bespoke solutions for each data type, ultimately resulting in convoluted, hard-to-manage data infrastructures and out-of-control licensing and operational costs.

Science 59

Science Government Engineering Licensing 59

thought leadership

MAY 29, 2025

On Tuesday, September 25 th , the FDA published a draft guidance containing recommendations on good review management principles and practices (GRMPs) for new drug applications (NDAs), Biologics license applications (BLAs), or efficacy supplements/supplements with clinical data.

Biosimilars 52

Biosimilars Licensing Licensing FDA 52

The Pharma Data

JULY 2, 2025

The rights to felzartamab were licensed to Human Immunology Biosciences (HI-Bio) , which Biogen acquired in July 2024. About Felzartamab Felzartamab is a fully human monoclonal antibody against CD38, originally developed by MorphoSys AG (now MorphoSys GmbH, a Novartis company).

Trials 40

Trials Disease FDA Approval Treatment 40

New Drug Approvals

MAY 17, 2025

It is administered as an intrathecal injection. [3] 3] The most common side effects include fatigue, arthralgia (joint pain), increased cerebrospinal (brain and spinal cord) fluid white blood cells, and myalgia (muscle pain). [3] 4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] 3 November 2006.

FDA Approval 62

FDA Approval FDA Treatment Clinical Trials 62

The Pharma Data

JUNE 24, 2025

A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors. This agreement grants Bayer exclusive global rights to develop, manufacture, and commercialize the MTA-cooperative PRMT5 inhibitor.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

New Drug Approvals

APRIL 25, 2025

External links Clinical trial number NCT04191499 for “A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)” at ClinicalTrials.gov Clinical (..)

FDA 57

FDA FDA Approval Therapies Trials 57

Drug Target Review

MARCH 4, 2025

During his career, Mark has negotiated and managed six M&A transactions, raised more than half a billion dollars in equity and debt financings, and negotiated numerous licensing agreements. He is a CPA and started his career in the high technology and biotechnology practices of Ernst & Young.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Drug Target Review

MARCH 17, 2025

Donello was most recently Vice President of External Science & Innovation at Allergan/AbbVie, where he led R&D innovation efforts to develop strategic collaborations, in-license clinical-stage assets and evaluate M&A opportunities.

Treatment 52

Treatment Licensing Licensing Science 52

New Drug Approvals

JUNE 11, 2025

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] Side effects of gepirone include dizziness , nausea , insomnia , abdominal pain , and dyspepsia (indigestion). [1] 1] Gepirone acts as a partial agonist of the serotonin 5-HT 1A receptor. [1]

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

Drug Target Review

APRIL 14, 2025

As a senior attorney at the law firm Cooley LLP, his practice focused on equity financing and M&A transactions, and negotiating complex biotech licensing and collaboration deals.

Therapies 52

Therapies Marketing Drug Development Treatment 52

New Drug Approvals

MAY 9, 2025

. “RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models” Anti-Cancer Drugs. 26 (9): 948956. doi : 10.1097/CAD.0000000000000271. 0000000000000271. PMC 4560273. PMID 26164151.

FDA 62

FDA Pharmacokinetics Therapies Treatment 62

The Pharma Data

JULY 2, 2025

Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) and granted it priority review status, seeking to update the U.S. The product was developed under a licensing agreement with Bristol Myers Squibb.

Trials 52

Trials FDA Licensing Licensing 52

SugarCone Biotech

JULY 6, 2025

Bristol Myers Squibb (BMS) licensed rights to iza-bren in 2023 and they and partner Sysimmune/Biokin have sponsored clinical studies across cancer indications without limiting these to settings of EGFR resistance or of NRG1 fusion.

Drug Development 56

Drug Development Drugs Clinical Trials Therapies 56

New Drug Approvals

JULY 2, 2025

then was licensed to Lilly in 2018. [1] Orforglipron ( LY-3502970 ) is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] 1] It was discovered by Chugai Pharmaceutical Co. percentage points from a starting level of 8%. [1] kg), on average after 40 weeks. [1]

Small Molecule 57

Small Molecule Clinical Trials Trials Pharmacokinetics 57

Drug Patent Watch

JANUARY 14, 2025

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. Intellectual property is often a central issue in pharmaceutical negotiations, particularly in licensing deals and partnerships.

Pharmaceuticals 54

Pharmaceuticals Compliance Licensing Licensing 54

New Drug Approvals

APRIL 2, 2025

1] [2] Clinical data Pronunciation /suztrdin/ soo-ZE-tri-jeen Trade names Journavx Other names VX-548 AHFS / Drugs.com Journavx License data US DailyMed : Suzetrigine Routes of administration By mouth Drug class Na v 1.8 It exerts its action on dorsal root ganglion. [3] 2] Names Suzetrigine is the international nonproprietary name. [12]

FDA 62

FDA Therapies Trials Treatment 62

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. and European drugmakers.

Disease 109

Disease Licensing Licensing Therapies 109

New Drug Approvals

JUNE 29, 2025

External links Clinical trial number NCT04395677 for “A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene” at ClinicalTrials.gov Clinical trial number NCT04919811 for “Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)” at ClinicalTrials.gov Clinical data Trade names Ibtrozi License (..)

International 62

International FDA Clinical Trials Treatment 62

New Drug Approvals

JULY 10, 2025

LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook Anthony Melvin Crasto Dr. | Facebook Twitter FACEBOOK join me on twitter Anthony Melvin Crasto Dr. | twitter +919321316780 call whatsaapp EMAIL.

FDA 57

FDA Treatment Small Molecule International 57

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Delilah Alvarado Staff Reporter post share post print email license The Food and Drug Administration on July 10, 2025, issued Moderna a full approval in children for its COVID-19 vaccine Spikevax. Kennedy Jr., who has pushed for policy changes around mRNA vaccines in particular.

Vaccine 226

Vaccine FDA Therapies Licensing 226

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat.

Drugs 215

Drugs Licensing Licensing Therapies 215

New Drug Approvals

JUNE 15, 2025

External links Clinical trial number NCT04115293 for “Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)” at ClinicalTrials.gov Clinical data Trade names Zilbrysq Other names RA101495 AHFS / Drugs.com Monograph MedlinePlus a624002 License data US DailyMed : Zilucoplan Pregnancy category (..)

FDA 57

FDA Treatment Production Clinical Trials 57

New Drug Approvals

MAY 8, 2025

External links “Pirtobrutinib” National Cancer Institute. 16 February 2023. “Pirtobrutinib” NCI Drug Dictionary.

FDA Approval 52

FDA Approval FDA Therapies Trials 52